Evidence map›Paper›PMID 41266381›Full record

ArticleNPJ vaccines2025

Optimal deployment of limited vaccine supplies to control mpox outbreaks.

Matthew T Berry, C Raina MacIntyre, Deborah Cromer, Adam Hacker, Miles P Davenport, David S Khoury

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matthew T BerryInfection Analytics Program, Kirby Institute, UNSW Sydney, Kensington, NSW, 2052, Australia.
C Raina MacIntyreBiosecurity Program, Kirby Institute, UNSW Sydney, Kensington, NSW, 2052, Australia.
Deborah CromerInfection Analytics Program, Kirby Institute, UNSW Sydney, Kensington, NSW, 2052, Australia.
Adam HackerCoalition for Epidemic Preparedness Innovations, Post box 1030 Hoff, 0218, Oslo, Norway.
Miles P DavenportInfection Analytics Program, Kirby Institute, UNSW Sydney, Kensington, NSW, 2052, Australia.
David S KhouryInfection Analytics Program, Kirby Institute, UNSW Sydney, Kensington, NSW, 2052, Australia. dkhoury@kirby.unsw.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mpox outbreaks in central and East Africa have been declared a public health emergency of international concern by the World Health Organization. Fortunately, real-world effectiveness studies of the MVA-BN vaccine indicate that it has an effectiveness of 74% after one dose, and 82% after two doses against mpox. However, given the very limited availability of vaccines, there remain questions around the optimal deployment of limited MVA-BN doses. In this study, we consider whether more mpox cases might be averted by following the traditional two-dose vaccine regimen (4 week dosing interval), or by giving a single dose of MVA-BN to as many individuals as possible. We find that the optimal strategy depends on (i) the degree to which a subpopulation might be at higher risk of mpox, or severe mpox, and (ii) how long ago the first dose was administered to the most at-risk subpopulation.

Identifiers

PMID41266381
PMCPMC12635158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.